Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 3/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PLG | P00747 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14031132 | 0.88 | GAA (0.35) | GAAF2F10PRSS1MME | |
| SCHEMBL14049377 | 0.83 | GAA (0.36) | GAAF2F10PRSS1BACE1 | |
| SCHEMBL1655875 | 0.82 | BIRC3 (0.38) | GAAF2F10PRSS1ITGB1 | |
| SCHEMBL12343884 | 0.81 | F2 (0.33) | GAAF2F10PRSS1BACE1 | |
| SCHEMBL5530641 | 0.80 | ADRB3 (0.45) | GAAF2F10PRSS1 | |
| SCHEMBL5534015 | 0.80 | ADRB3 (0.45) | GAAF2F10PRSS1 | |
| SCHEMBL5530647 | 0.80 | ADRB3 (0.45) | GAAF2F10PRSS1 | |
| SCHEMBL5534012 | 0.80 | ADRB3 (0.45) | GAAF2F10PRSS1 | |
| SCHEMBL7876742 | 0.80 | ADRB3 (0.45) | GAAF2F10PRSS1 | |
| SCHEMBL2624064 | 0.80 | ADRB3 (0.45) | GAAF2F10PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268777-B2 | Oximyl macrocyclic derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| WO-2009073713-A1 | OXIMYL MACROCYCLIC DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191153-A1 | OXIMYL MACROCYCLIC DERIVATIVES | CYP3A4, CYP4A22, HCCS | GAA 424/4885F2 562/4885F10 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.